EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ChunLab Inc (311690) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of ChunLab Inc KRW 2,585, price KRW 3,710, upside -30.3%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

CI Thin data Sep 24, 2026

ChunLab Inc

311690 · KQ

Weak valuationQuality is weak on top of the rich price.

!Fair value 2,585 KRW · Overvalued (−30%)
!Quality 39/100
!Weak Growth (revenue 5y −7.0 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch ChunLab Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56,299 KRW 3,185 KRW Fair Value 2,585 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 3,185 KRW – 56,299 KRW · fair‑value band 1,706 KRW – 3,232 KRW · the 3,710 KRW price screens above the 2,585 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow ChunLab in your weekly email

Every Wednesday you see whether ChunLab is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis.

Show more

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics analysis portal for microbial research; EzBioCloud Pro, a next-generation analysis platform for infection diagnosis and microbial bioinformatics analysis; Gut Inside, a microbiome testing service; and TrueBac ID, a cloud-based service platform that can identify various bacterial species based on genomic data. The company was formerly known as ChunLab, Inc. and changed its name to CJ Bioscience, Inc. in December 2021. CJ Bioscience, Inc. was founded in 2009 and is based in Seoul, South Korea.

Stock analysis

ChunLab Inc (311690) currently trades at 3,710 KRW, while our model-based Fair Value estimate is 2,585 KRW, implying the stock looks roughly 43.5% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 1,706 KRW (bear) to 3,232 KRW (bull), the price of 3,710 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

ChunLab Inc reported revenue of 3.7B KRW in FY2025 versus 4.4B KRW in FY2021, a compound −4.1%/yr. Reported net income was −24.0B KRW in FY2025.

Key figures

Market cap 48.5B KRW (≈ $35.6M) · P/S ratio 13.4 · Return on equity −38.4% · Return on assets (EBIT) −30.1% · Operating margin −682% · Revenue (TTM) 3.6B KRW · Revenue growth (YoY) −14.2% · Free cash flow −23.5B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −30%, 311690 screens richer than that median.

Fair Value models

Bear 1,706 KRW Fair Value 2,585 KRW Bull 3,232 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2,053 KRW 2,751 KRW 4,105 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 2,053 KRW 2,751 KRW 4,105 KRW 54

Open the full fair value analysis →

Notify me when 311690 reaches fair value

Put 311690 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 39/100

Of which business quality 39 · Market factors (momentum, volatility) 24

Profitability 0
Margins and returns on capital today
Quality Growth 61
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 64
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−160.3% (2020) → −671.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

311690 screens 43% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare ChunLab Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −30% · Above median
Profitability
Return on assets −19% · Below median
Growth and dividend
Revenue growth −14% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.01× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ChunLab Inc · Fair Value
2,585 KRW −43%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ChunLab Inc Fair Value". https://www.fairvalue-calculator.com/stock/311690

Frequently asked questions

Is ChunLab Inc (311690) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,585 KRW versus a price of 3,710 KRW, about −30% upside (overvalued).
What is the fair value of 311690?
Our model-based fair value for ChunLab Inc is 2,585 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,710 KRW.
What is the quality score of 311690?
ChunLab Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChunLab Inc (311690)?
Our model-based price target is the fair value of 2,585 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1,706 KRW, optimistic scenario 3,232 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ChunLab Inc stock forecast for 2026?
Our models put fair value at 2,585 KRW, about −30% upside versus a price of 3,710 KRW (overvalued). Cautious scenario 1,706 KRW, optimistic scenario 3,232 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ChunLab Inc (311690)?
ChunLab Inc reported trailing-twelve-month revenue of about 3.6B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ChunLab Inc (311690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChunLab Inc it is 2,585 KRW per share (as of Sep 24, 2026), against a price of 3,710 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ChunLab Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 311690 trades above its calculated fair value: price 3,710 KRW, fair value 2,585 KRW, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 311690?
No. The price is what the market pays today (3,710 KRW); the fair value is what the company's own numbers justify (2,585 KRW). For ChunLab Inc the two are 1,125 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ChunLab Inc worth?
The market values ChunLab Inc at about 48.5B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,710 KRW; our models calculate a fair value of 2,585 KRW per share.
What do the bullish and bearish scenarios say about 311690?
Our models span a range for ChunLab Inc: cautious scenario 1,706 KRW, base 2,585 KRW, optimistic 3,232 KRW per share (as of Sep 24, 2026, price 3,710 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ChunLab Inc (311690)?
Balance-sheet figures for ChunLab Inc (as of Sep 24, 2026): return on equity −38.4%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 311690 from its 52-week high?
ChunLab Inc trades at 3,710 KRW, about 63% below its 52-week high of 10,160 KRW and 16% above the low of 3,185 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,585 KRW is for.
Which stocks are comparable to ChunLab Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChunLab Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 3,710 KRW, calculated fair value 2,585 KRW (−30%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 311690 calculated?
We run ChunLab Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,585 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. ChunLab Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChunLab Inc (311690)?
The closing price on Sep 23, 2026 was 3,710 KRW. Our model-based fair value is 2,585 KRW, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChunLab Inc right now?
The price sits above even our optimistic bull case (3,232 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,706 KRW to 3,232 KRW) leaves room in how you read the outcome.

Key figures of ChunLab Inc

How large is the market capitalisation of ChunLab Inc (311690)?
The market capitalisation of ChunLab Inc is 48.5B KRW (≈ $35.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChunLab Inc (311690)?
The price-to-sales ratio of ChunLab Inc is 13.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of ChunLab Inc (311690)?
The return on equity (ROE) of ChunLab Inc is −38.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChunLab Inc (311690)?
On an EBIT basis the return on assets of ChunLab Inc is −30.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChunLab Inc (311690)?
The operating margin of ChunLab Inc is −682% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChunLab Inc (311690)?
Revenue at ChunLab Inc is growing −14.2% versus a year earlier (3y avg −3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ChunLab Inc (311690) generate?
The free cash flow of ChunLab Inc is −23.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ChunLab Inc (311690) carry?
The net debt of ChunLab Inc is 21.8B KRW (fiscal year 2020). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ChunLab Inc in the live analysis

One click puts ChunLab Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.